<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251112067973N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-28</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Platelet-Rich Fibrin (PRF) and Platelet-Rich Plasma (PRP) Injections in the Treatment of Androgenetic Alopecia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Efficacy of Platelet-Rich Fibrin (PRF) and Platelet-Rich Plasma (PRP) Injections in the Treatment of Androgenetic Alopecia: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/93630</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After eligibility has been confirmed according to the predefined inclusion and exclusion criteria, participants will be allocated to the PRF or PRP group using simple randomization. A unique study code will be assigned to each eligible participant, and treatment allocation will be determined according to a pre-generated random sequence. Each participant will have an equal probability of being allocated to either study group. Given the total sample size of 24 participants, 12 participants will be allocated to the PRF group and 12 participants to the PRP group. Group allocation will be performed after confirmation of eligibility and before initiation of the intervention, Blinding description: he participants, outcome assessor, and data analyst will be blinded to treatment allocation. Treatment allocation will be performed by an individual independent of outcome assessment and statistical analysis. The outcome assessor will not have access to treatment allocation during clinical assessment and evaluation of the relevant images/outcome measures. The data analyst will analyze the dataset using coded treatment groups without knowledge of the identity or nature of the treatment groups. If required, the allocation codes will be unblinded after completion of outcome assessment and final statistical analysis.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Androgenic alopecia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Participants in this group will receive localized scalp injections of platelet-rich plasma (PRP). For PRP preparation, 10–20 mL of venous blood will be collected from each participant into tubes containing sodium citrate (3.2–3.8%) as an anticoagulant. The blood sample will then be centrifuged at 3000 rpm for 12 minutes. Following centrifugation, the platelet-rich plasma fraction will be separated from the other blood components and, if required, activated with 10% calcium chloride prior to injection. The prepared PRP will be administered by localized injection into the predetermined scalp area with the lowest hair density or the margin of the hair-loss area. Injections will be performed at weeks 0, 4, and 8. Participants will be followed throughout the study for treatment response and any potential injection-related adverse events. Intervention 2: Intervention group: Participants in this group will receive localized scalp treatment with platelet-rich fibrin (PRF). For PRF preparation, 10–20 mL of venous blood will be collected into sterile tubes without the use of any anticoagulant. The blood sample will be immediately centrifuged, within a maximum of 1 minute after collection, at 1500 rpm for 4 minutes. Following centrifugation, three layers will form: a platelet-rich fibrin clot (PRF clot) in the middle, plasma in the upper layer, and red blood cells in the lower layer. After separation, the PRF clot will be used directly or prepared as a membrane when required. The PRF will be administered by localized injection into the predetermined scalp area with the lowest hair density or the margin of the hair-loss area. Treatment will be performed at weeks 0, 4, and 8. Participants will be followed throughout the study for treatment response and any potential injection-related adverse events.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data collected during the study, including demographic characteristics, clinical outcome measures, ultrasonographic measurements, treatment allocation, treatment exposure, and safety laboratory data, may be shared upon reasonable request. The shared dataset will not contain directly identifying personal information. Study-related documents, including the study protocol and statistical analysis plan, may also be made available upon reasonable request. Data will not be publicly posted in an identifiable or unrestricted form.

When:
Access to de-identified individual participant data and study-related documents will begin 6 months after publication of the primary study results and will remain available for at least 5 years thereafter, subject to ethical and institutional requirements.

To whom:
Researchers and academic or scientific investigators from universities, research institutions, or other qualified organizations may submit a request for access. Requests from investigators outside academic institutions may also be considered if the proposed use meets the study's ethical and scientific requirements.

Conditions:
Data may be used for scientifically and ethically appropriate research purposes, including secondary analyses, methodological research, and systematic reviews or meta-analyses. Access will be limited to de-identified data and will not permit attempts to re-identify participants. The proposed use must be consistent with the original informed consent and applicable ethical and institutional requirements. Data may not be used for commercial purposes or redistributed to third parties without prior approval.

Where to obtain:
Requests should be submitted to the principal investigator,

How to obtain:
Applicants should submit a written request describing the purpose of the proposed research, the specific data or documents requested, the proposed analyses, and the intended dissemination of the results. Each request will be reviewed by the principal investigator and the research team for scientific merit, ethical compatibility, participant confidentiality, and compliance with institutional requirements. Additional documentation, such as an institutional affiliation or research ethics approval, may be requested when appropriate. Approved data will be provided in a de-identified format after completion of the required review and any applicable data-use agreement. Requests will normally be reviewed within 4 to 8 weeks of receipt of complete documentation.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parisa Sadat Mirsafaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi Hospital, Razi Alley, Vahdat-e Eslami St., below Vahdat-e Eslami Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5557 5141</telephone>
        <email>tumspr@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parisa Sadat Mirsafaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi Hospital, Razi Alley, Vahdat-e Eslami St., below Vahdat-e Eslami Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5557 5141</telephone>
        <email>tumspr@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of androgenetic alopecia based on clinical examination and trichoscopy
Active hair loss during the preceding 12 months
Androgenetic alopecia classified as grade II to VI according to the Hamilton-Norwood scale or grade I to III according to the Ludwig classification
Written informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any treatment for hair loss during the preceding 3 months
History of hair transplantation
Systemic or scalp diseases that may affect hair growth
Pregnancy
Unwilling to participate in the study or continue participation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L64</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Androgenic alopecia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants in this group will receive localized scalp injections of platelet-rich plasma (PRP). For PRP preparation, 10–20 mL of venous blood will be collected from each participant into tubes containing sodium citrate (3.2–3.8%) as an anticoagulant. The blood sample will then be centrifuged at 3000 rpm for 12 minutes. Following centrifugation, the platelet-rich plasma fraction will be separated from the other blood components and, if required, activated with 10% calcium chloride prior to injection. The prepared PRP will be administered by localized injection into the predetermined scalp area with the lowest hair density or the margin of the hair-loss area. Injections will be performed at weeks 0, 4, and 8. Participants will be followed throughout the study for treatment response and any potential injection-related adverse events.</i_keyword>
      <i_keyword>Intervention group: Participants in this group will receive localized scalp treatment with platelet-rich fibrin (PRF). For PRF preparation, 10–20 mL of venous blood will be collected into sterile tubes without the use of any anticoagulant. The blood sample will be immediately centrifuged, within a maximum of 1 minute after collection, at 1500 rpm for 4 minutes. Following centrifugation, three layers will form: a platelet-rich fibrin clot (PRF clot) in the middle, plasma in the upper layer, and red blood cells in the lower layer. After separation, the PRF clot will be used directly or prepared as a membrane when required. The PRF will be administered by localized injection into the predetermined scalp area with the lowest hair density or the margin of the hair-loss area. Treatment will be performed at weeks 0, 4, and 8. Participants will be followed throughout the study for treatment response and any potential injection-related adverse events.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change in overall hair density. Timepoint: before initiation of treatment, and at the third and sixth months after treatment initiation. Method of measurement: Hair density will be assessed using a trichoscope by counting the number of hairs within a predefined scalp area, with the patient's head maintained in a standardized and fixed position.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Change in hair density in the predefined scalp area. Timepoint: before initiation of treatment, and at the third and sixth months after treatment initiation. Method of measurement: Hair density will be assessed using a trichoscope. A predefined circular area with a diameter of 10 millimeters and an area of 100 square millimeters will be evaluated, and the number of hairs within this area will be counted.</sec_outcome>
      <sec_outcome>Change in hair shaft thickness. Timepoint: before initiation of treatment, and at the third and sixth months after treatment initiation. Method of measurement: The mean hair shaft thickness of five hairs within the predefined scalp area will be measured and recorded using trichoscopy in micrometers. Hairs with a thickness greater than 40 micrometers will be classified as terminal hairs, whereas hairs with a thickness less than 40 micrometers will be classified as vellus hairs.</sec_outcome>
      <sec_outcome>Overall Treatment Response Based on Changes in Lesion Density on Clinical Photographs. Timepoint: At baseline before initiation of the intervention and at month 6 after initiation of the intervention. Method of measurement: Changes in lesion density will be evaluated based on clinical photographs of the participants. Standardized photographs will be obtained in frontal and vertex views with the head maintained in a fixed position. The photographs will be assessed by the participants themselves and by two dermatologists. The degree of change in lesion density will be evaluated using a standardized seven-point grading system: marked decrease in density (−3), moderate decrease in density (−2), mild decrease in density (−1), no change (0), mild increase in density (+1), moderate increase in density (+2), and marked increase in density (+3).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2027-07-25</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine- Tehran University of Medical Sciences</contact_name>
        <contact_address>School of Medicine, Tehran University of Medical Sciences, Ghods Street, Keshavarz Boulevard, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
